
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline
January 29, 2025
CEO Rob Fried details the production of a supplement that enhances cell repair and energy metabolism, the new normal in healthy aging.
January 29, 2025
January 14, 2025
July 16, 2024
July 9, 2024
We use cookies to improve your experience on our site, to show you personalized advertising, and as otherwise described in our Cookie Policy . To find out more, read our Privacy Policy and our Cookie Policy.